30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: Alphatec Spine

$51.0MM, +2% (U.S. $34.8MM, +3%; ex-U.S. $16.2MM, +1%)

  • Less Invasive Products +9% overall, +35% ex-U.S.
  • Biologics U.S. +18%


  • Price had less of an impact in the U.S. than at any time in the last 2 years
  • Biologics growth reflects deeper sales into procedures
  • In final stages of product approval in CHina


Arsenal Fixation System update:

  • Launched 25% of instrument sets to be available at full launch in early 2015; initiated development of set utilization and replenishment process
  • >200 procedures completed, beta launch to expand in mid-4Q, with an additional 25% of instrument sets
  • Averaged >50% of new business vs. existing customers